It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The individual results of SARS-CoV-2 serological tests measured after the first pandemic wave of 2020 cannot be directly interpreted as a probability of having been infected. Plus, these results are usually returned as a binary or ternary variable, relying on predefined cut-offs. We propose a Bayesian mixture model to estimate individual infection probabilities, based on 81,797 continuous anti-spike IgG tests from Euroimmun collected in France after the first wave. This approach used serological results as a continuous variable, and was therefore not based on diagnostic cut-offs. Cumulative incidence, which is necessary to compute infection probabilities, was estimated according to age and administrative region. In France, we found that a “negative” or a “positive” test, as classified by the manufacturer, could correspond to a probability of infection as high as 61.8% or as low as 67.7%, respectively. “Indeterminate” tests encompassed probabilities of infection ranging from 10.8 to 96.6%. Our model estimated tailored individual probabilities of SARS-CoV-2 infection based on age, region, and serological result. It can be applied in other contexts, if estimates of cumulative incidence are available.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Inserm, Institut Pierre-Louis d’épidémiologie et de santé publique, Sorbonne Université, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389); AP-HP. Sorbonne Université, Département de santé publique, Hôpital Saint-Antoine, Paris, France (GRID:grid.412370.3) (ISNI:0000 0004 1937 1100)
2 Aix Marseille Univ, Unité des Virus Émergents, UVE, IRD 190, INSERM 1207, IHU Méditerranée Infection, Marseille, France (GRID:grid.5399.6) (ISNI:0000 0001 2176 4817)
3 Paris University, Paris, France (GRID:grid.462420.6); UVSQ, Inserm UMS 11, Université Paris-Saclay, Université de Paris, Villejuif, France (GRID:grid.12832.3a) (ISNI:0000 0001 2323 0229)
4 UVSQ, Inserm, Gustave Roussy, CESP UMR1018, Université Paris-Saclay, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); University of Florence, Department of Statistics, Computer Science and Applications, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
5 University of Paris (CRESS), Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center, Bobigny, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
6 CEPH-Biobank, Fondation Jean Dausset-CEPH (Centre d’Etude du Polymorphisme Humain), Paris, France (GRID:grid.417836.f) (ISNI:0000 0004 0639 125X)
7 Université de Paris, Centre for Research in Epidemiology and StatisticS (CRESS), Inserm, INRAE, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
8 UVSQ, Inserm UMS 11, Université Paris-Saclay, Université de Paris, Villejuif, France (GRID:grid.12832.3a) (ISNI:0000 0001 2323 0229)
9 UVSQ, Inserm, Gustave Roussy, CESP UMR1018, Université Paris-Saclay, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388)
10 EPIPAGE-2 Joint Unit, Paris, France (GRID:grid.508487.6)
11 ELFE Joint Unit, Paris, France (GRID:grid.508487.6)
12 Santé Publique France, Paris, France (GRID:grid.493975.5) (ISNI:0000 0004 5948 8741)
13 Inserm, Institut Pierre-Louis d’épidémiologie et de santé publique, Sorbonne Université, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389)
14 Inserm, Paris, France (GRID:grid.7429.8) (ISNI:0000 0001 2186 6389)
15 Aviesan, Inserm, Paris, France (GRID:grid.7429.8) (ISNI:0000 0001 2186 6389)